Project Grant R01CA303112
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on April 24, 2026, with completion targeted for March 31, 2028. The research project addresses colorectal cancer (CRC) recurrence by developing and implementing novel microfluidics-based technology to isolate, culture, and characterize minimal residual disease (MRD)—cancer cells...
- Federal Grant Award Summary Duke University received a $668,691 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective March 11, 2026 through February 28, 2031. The award funds a randomized controlled trial testing two integrated interventions designed to improve treatment outcomes and quality of life for older women (age 65+) with hormone receptor-positive breast cancer undergoing adjuvant aromatase inhibitor (AI)...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.88 million Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on September 23, 2025, with completion targeted for August 31, 2029. The award supports fundamental research integrating genome-wide association study (GWAS) data with single-cell omics technologies to identify and characterize the cellular effectors underlying...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $626,475 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on June 15, 2026, with a completion date of May 31, 2031. This award funds fundamental research investigating the role of integrin alpha-6 (a6) in breast cancer metastasis to the leptomeninges—the cerebrospinal fluid-containing membranes surrounding the brain and spinal cord....
- Federal Grant Award Summary Duke University's Office of Research Administration was awarded $402,135 by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, with completion targeted for April 30, 2029. The project involves the development and optimization of SCHICAR (Single-Cell High-resolution 3D Genome Interactions, Chromatin Accessibility, and transcRiptomes), a novel tri-modal single-cell platform designed to simultaneously capture...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $610,459 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, with completion anticipated by April 30, 2031. This five-year award funds fundamental research investigating NEUROD1 and cell fate plasticity in olfactory neuroblastoma (ONB), a rare and aggressive tumor with limited treatment options. The research...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $120,403 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded on June 1, 2026, with a completion date of May 31, 2027. This award supports research development focused on pancreatic ductal adenocarcinoma (PDAC) detection and patient risk stratification. The project delivers ultrasensitive maximum depth sequencing (MDS) services...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Project Grant Award Summary Duke University, through its Office of Research Administration, received a $607,157 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) beginning May 1, 2026 and concluding April 30, 2031. This five-year research initiative will deliver fundamental cancer biology research aimed at understanding neuroendocrine prostate cancer (NEPC) mechanisms and identifying therapeutic targets. Specifically, the...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $179,276 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2025, with a completion date of May 31, 2027. The award supports research investigating the role of the ABL kinase-regulated HIF-1A-TAZ signaling pathway in promoting brain metastasis in triple-negative breast cancer (TNBC). The project deliverables include...
Duke University's Office of Research Administration received a $616,652 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) effective July 1, 2026, through June 30, 2031. The project addresses a critical clinical gap by developing the first prognostic classification system for patients with recurrent breast cancer (RBC). The primary deliverable is a multi-institutional tumor registry leveraging retrospective observational cohort data from six major U.S. sites, containing granular clinical details of disease characteristics, treatment protocols, and patient outcomes necessary for accurate prognostic staging of RBC patients. The registry will serve as a foundational tool to enable healthcare providers to discuss prognosis and treatment recommendations with RBC patients using evidence-based staging criteria similar to those established for primary breast cancer diagnoses. Working in collaboration with a community advisory board throughout the project period, Duke University will develop a database containing sufficient clinical data to identify key predictors of post-recurrence survival and establish standardized assessments for RBC prognostic classification. This database represents the first comprehensive prognostic staging system designed specifically for the approximately one-third of early-stage breast cancer patients who develop recurrence after initial treatment.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $616.7k | 6/16/26 |